PJSC SIC Borshchahivskiy Chemical Pharmaceutical Plant (BCPP, Kyiv) may obtain a license to produce baby food and dietary food products.
As the company reported in the information disclosure system of the National Securities and Stock Market Commission (NSSMC), the issue of obtaining such licenses at the initiative of shareholder Aletber Limited (Cyprus) is on the agenda of the shareholders’ meeting to be held on April 30.
By the end of 2023, BCPP increased production by 17.6% compared to 2022 to almost UAH 1.866 billion, but in physical terms it decreased by 3.3% to 34.8 million packs. At the same time, 40.3 million packs were sold last year, which is 7.8% less than in 2022, while total sales increased by 16.5% to UAH 1.806 billion.
In 2023, BCPP’s net profit increased by 3.38% compared to 2022 to UAH 262.863 million.
As of the first quarter of 2023, 31.8% of BCPP shares were owned by the pharmaceutical company Pharmaceutical Firm “Darnitsa” (Kyiv).
According to the Opendatabot system, the ultimate beneficiaries of BCPP are also the beneficiary of the pharmaceutical company “Darnitsa” Hlib Zagoriy, Yevhen Sova and Tetiana Artemenko.
PJSC SIC Borshchahivskiy Chemical Pharmaceutical Plant (BCPP, Kyiv) increased production by 17.6% in 2023 compared to 2022, to almost UAH 1.866 billion, but reduced it by 3.3% in physical terms, to 34.8 million packs.
According to the plant’s information disclosure system, the company sold 40.3 million packs last year, which is 7.8% less than a year earlier, while total sales increased by 16.5% to UAH 1.806 billion.
At the same time, 29.4 million packs were sold in the domestic market (9.9% less than a year earlier) for UAH 1.537 billion (an increase of 16.2%).
At the same time, exports of products in 2023 increased by 18.5% in monetary terms to UAH 269 million, while decreasing by 1.7% in physical terms to 10.9 million packs.
BCPP notes that about 52% of the total product range last year was sold outside the country. In particular, 52% of export deliveries were made to neighboring countries, 48% – to Australia, the Middle East, Asia, Europe, North America and the Caribbean.
In 2023, the production nomenclature amounted to about 130 items of medicinal products in nine therapeutic areas, veterinary products, dietary supplements and extracts. In particular, the Company launched seven new products, including respiratory, digestive and metabolic, nervous system, musculoskeletal, antibiotic and dietary supplements.
Capital investments in the company’s own development in 2023 amounted to UAH 64.9 million.
In 2022, BCPP reduced its net profit by 24.8% to UAH 254.275 million. Net profit for 2020 increased by 1.7 times compared to 2019 to UAH 332.847 million.
As of the first quarter of 2023, 31.8% of BCPP shares were owned by the pharmaceutical company PrJSC “Pharmaceutical Firm “Darnitsa” (Kyiv).
According to the Opendatabot system, the ultimate beneficiaries of BCPP are also the beneficiary of the pharmaceutical company “Darnitsa” Hlib Zagoriy, Yevhen Sova and Tetiana Artemenko.
